Objectives: Tachycardia is common in septic shock, but many patients with septic shock are relatively bradycardic. The prevalence, determinants, and implications of relative bradycardia (heart rate, < 80 beats/min) in septic shock are unknown. To determine mortality associated with patients who are relatively bradycardic while in septic shock. Design: Retrospective study of patients admitted for septic shock to study ICUs during 2005ICUs during -2013. Setting: One large academic referral hospital and two community hospitals. Patients: Adult patients with septic shock requiring vasopressors. Intervention: None. Measurements: Primary outcome was 28-day mortality. We used multivariate logistic regression to evaluate the association between relative bradycardia and mortality, controlling for confounding with inverse probability treatment weighting using a propensity score. Results: We identified 1,554 patients with septic shock, of whom 686 (44%) met criteria for relative bradycardia at some time. Twenty-eight-day mortality in this group was 21% compared to 34% in the never-bradycardic group (p < 0.001). Relatively bradycardic patients were older (65 vs 60 yr; p < 0.001) and had slightly lower illness severity (Sequential Organ Failure Assessment, 10 vs 11; p = 0.004; and Acute Physiology and Chronic Health Evaluation II, 27 vs 28; p = 0.008). After inverse probability treatment weighting, covariates were balanced, and the association between relative bradycardia and survival persisted (p < 0.001). Conclusions: Relative bradycardia in patients with septic shock is associated with lower mortality, even after adjustment for confounding. Our data support expanded investigation into whether inducing relative bradycardia will benefit patients with septic shock. (Crit Care Med 2017; 45:225-233) 
S eptic shock is a common, complex syndrome associated with substantial morbidity and mortality (1) (2) (3) . Patients with septic shock have an acute dysregulated systemic response to infection leading to organ dysfunction and cardiovascular compromise, generally necessitating infusions of vasopressor medications in an ICU (2, 4, 5) .
Septic shock leads to impaired tissue oxygenation and perfusion, increased oxidative stress, and dysregulated inflammatory response (5) (6) (7) . In the initial phase, septic shock represents in part a hypovolemic state due to vasoplegia and capillary leak ("distributive" shock), with defects in cardiac preload and afterload related to increased capillary permeability (6) and low vascular tone (8, 9) . Tachycardia may be a compensatory response to this reduced cardiac preload to maintain cardiac output (9) . After initial treatment and fluid resuscitation, however, adrenergic overstimulation (10) may contribute to persistence of tachycardia. Persistent tachycardia in septic shock may be associated with disruptions in cardiac function (11) , including increased myocardial oxygen consumption and impaired diastolic filling (12, 13) , as well as impairment of the baroreflex system (indicated by loss of heart rate [HR] variability) (14, 15) . Observations from small cohorts suggest that tachycardia in septic shock is associated with higher mortality (16, 17) .
On the other end of the spectrum, some patients with septic shock are relatively bradycardic (18, 19) with HRs less than 80-90 beats/min. This relative bradycardia may reflect lower sympathetic and/or higher parasympathetic tone; its implications are not yet known.
We retrospectively investigated the association of relative bradycardia with mortality in septic shock, controlling for the propensity to be relatively bradycardic. We hypothesized that relative bradycardia in septic shock would be associated with lower mortality.
MATERIALS AND METHODS

Patients
We identified patients with septic shock drawn from two cohorts of patients admitted to Intermountain Healthcare hospitals (Fig. 1) . From both cohorts, we included only adult patients admitted to ICUs with septic shock requiring vasopressor therapy. The first cohort is a subset of a quality improvement cohort (20) of septic patients admitted to a study ICU from January 2006 to May 2013 (n = 2,687). We included the subset of 1,353 patients with septic shock (as defined in then-current consensus guidelines [21] ) receiving vasopressor infusion from the three study hospitals. The second cohort included patients with vasopressor-refractory shock from any cause, defined as requiring at least 1 μg/kg/ min of norepinephrine or equivalent (22) , admitted between August 1, 2005, and August 31, 2010 (n = 443). Within this cohort, we studied the 201 patients for whom sepsis was the cause of shock admitted to the same three hospitals. Neither cohort enrolled pregnant patients. We included only the first ICU admission for each patient. We assigned the 27 patients present in both cohorts to the vasopressor-refractory shock cohort.
The Intermountain Institutional Review Board (IRB number: 1014318) approved this study with waiver of informed consent.
Assessment of HR
In our prespecified primary analysis, we defined relative bradycardia as HR less than 80 beats/min, a threshold we chose because tachycardia in sepsis is often defined as a HR greater than 90-100 beats/min (4, 19) . Study ICUs electronically store 15 minute moving median values for vital signs.
Relative bradycardia was classified in three ways (Table 1) : dichotomously, extent of bradycardia, and weighted mean HR. For the primary, dichotomous definition, if no median HR exceeded the HR threshold for 60 minutes, the patient was considered to be bradycardic. We classified patients dichotomously as either ever bradycardic (if they had at least 1-hour-long episode of bradycardia) or never bradycardic. If a continuous bradycardic episode lasted longer than 1 hour, the entire period was counted as one episode. In a secondary definition, we measured extent of bradycardia by calculating the area under the curve (AUC) for HR less than 80 beats/min for each patient (eFig. 1, Supplemental Digital Content 1, http:// links.lww.com/CCM/C157), normalizing this area for the total time on vasopressors. Finally, we calculated the weighted mean HR while on vasopressors. HR data were collected while patients were receiving a vasopressor infusion.
Clinical Data
Trained reviewers abstracted each subject's medical record to verify the presence and etiology of septic shock (23, 24) . We calculated Acute Physiology and Chronic Health Evaluation (APACHE)-II (25), Sequential Organ Failure Assessment (SOFA) (26) , and Elixhauser (which includes the presence of hypothyroidism and diabetes mellitus) comorbidity scores (27, 28) . Presence of mechanical ventilation during admission was determined from the electronic medical record (EMR). Infusion rates of vasopressors (norepinephrine, epinephrine, dopamine, phenylephrine, and vasopressin) are automatically uploaded in real time to hospital EMRs. We analyzed all vasopressors administered during the ICU stay, converting them to norepinephrine-equivalent dosages according to standard equivalencies (22) . We also analyzed inotropic and chronotropic agents (dobutamine, isoproterenol, and milrinone) administered during the ICU stay. For each infusion, we calculated weighted mean dose, maximum dose, and total duration of administration. Weighted mean doses were normalized for the total time of infusion. The weighted mean of the mean arterial pressure (MAP) was normalized to the total time on vasopressors. We reviewed admission electrocardiograms (ECGs) for all patients. From ECGs, we abstracted HR/rhythm, ischemia or infarction, and conduction abnormalities. We identified the diagnosis of atrial fibrillation from ECGs and diagnostic codes (online data supplement, Supplemental Digital Content 1, http://links.lww.com/CCM/ C157). Ejection fraction (EF) was obtained from clinical echocardiography results. Transthoracic echocardiograms were reviewed for up to 1 year prior to and up to 48 hours after a reference time (online data supplement). We also determined whether patients had a permanent pacemaker prior to hospital admission and whether a pacemaker was placed during the index hospitalization by chart review.
We determined whether patients were receiving atrioventricular nodal blocking medications at admission (eList 1, Supplemental Digital Content 1, http://links.lww.com/ CCM/C157) based on the EMR. ICU medications (eTable 1, Supplemental Digital Content 1, http://links.lww.com/CCM/ C157) commonly associated with incident bradycardia were recorded if a bradycardic episode occurred within three halflives of the closest preceding medication administration.
Clinical Outcomes
Our prespecified primary outcome was 28-day all-cause mortality, determined from the Intermountain Death Record, which incorporates Utah state vital statistics. Secondary outcomes included hospital length of stay (LOS), ICU LOS, organ failure-free days, and vasopressor-free days. Organ failure-free days were calculated using SOFA scores: days on which the SOFA organ subscore was less than 2 were considered to be organ failure free (29) .
Statistical Methods
Primary Analysis. Our prespecified primary analysis was to assess the association between relative bradycardia (using the dichotomous definition, Table 1 ) and 28-day mortality using logistic regression, while controlling for the propensity to be bradycardic and other relevant covariates. Inverse probability of treatment weighting (IPTW) uses a propensity score to adjust for confounding in the logistic regression model (30, 31) . This method weights each patient by the inverse of the probability of being relatively bradycardic, resulting in a "pseudo" population, where the distributions of covariates are independent of bradycardia. In order to more accurately estimate the variance of the variable estimates, we stabilized the weights by the overall probability of being bradycardic. The propensity score was defined as the probability of being bradycardic based on a logistic regression model, where relevant predictors of bradycardia were identified from candidate predictors available upon admission (eTable 2, Supplemental Digital Content 1, http://links.lww.com/CCM/C157) using backward stepwise selection, which minimized the Akaike information criterion (AIC). We also used the AIC-minimizing backward stepwise selection procedure to build the primary regression model of mortality (details of all candidate predictors available in eTable 3, Supplemental Digital Content 1, http://links.lww.com/CCM/ C157). We modeled each vasopressor independently, to determine whether, for example, phenylephrine affected both HR and mortality.
Secondary and Sensitivity Analyses. In paired secondary analyses, we repeated the propensity-adjusted regression model using the extent of bradycardia or the weighted mean HR while on vasopressors. We performed a sensitivity analysis excluding the last 6 hours of vasopressor infusion (when patients were presumably dying or liberating from vasopressors). In an exploratory analysis to probe the effect of vasopressor initiation on HR, we calculated the weighted mean HR for the hour prior to and the hour after vasopressor initiation and calculated the percent change in HR associated with the initiation of vasopressors. As a final exploratory analysis, we calculated the change in weighted mean HR over the first 24 hours, which was defined as (weighted mean HR from 0 to 2 hr) -(weighted mean HR from 23 to 25 hr) and included this variable as a candidate predictor in the propensity model for mortality
We used effect plots to visualize the relationship between the extent of bradycardia and various outcomes. Hospital LOS, ICU LOS, organ failure-free days, and vasopressor-free days were modeled using propensity-adjusted linear regression with backward stepwise feature selection (eTable 3, Supplemental Digital Content 1, http://links.lww.com/CCM/C157). A Box-Cox transformation was applied to both hospital and ICU LOS for all regression analyses. All models were adjusted to control for study hospital.
Given the potential interest in mortality at thresholds besides our prespecified threshold of 80 beats/min, we explored whether there was a HR threshold at which predicted probability for 28-day mortality was minimized. Using the same methodology to identify relatively bradycardic patients described above, we identified patients considered "bradycardic" using HRs at multiple thresholds (50-140 beats/min at intervals of 5 beats/min). We determined the predicted probability of 28-day mortality, adjusted for admission APACHE II score, at each HR threshold. To limit the risk of type 1 error, we limited false discovery rate to 5% (32) . All analyses were conducted using the R Statistical Package, version 3.1.2 (33) .
RESULTS
We identified a total of 1,554 patients (Fig. 1) , of whom 686 (44%) were ever bradycardic. Admission characteristics for everbradycardic and never-bradycardic patients are displayed in Table 2 (eTable 4, Supplemental Digital Content 1, http://links. lww.com/CCM/C157). Bradycardic patients were older and had slightly lower APACHE II and SOFA scores than never-bradycardic patients. Total Elixhauser scores were similar, though bradycardic patients were more likely to have hypothyroidism.
Results of Primary Analysis
Overall 28-day mortality was 28% (n = 435). Mortality was significantly lower in the bradycardic group than in the never-bradycardic group (21% vs 34%; p < 0.001). The results of the primary propensity-adjusted regression analysis of 28-day mortality are displayed in Table 3 . Bradycardia was associated with significantly lower mortality (odds ratio [OR], 0.55; adjusted p < 0.001). In the propensity model, predictors of bradycardia included age, admission APACHE II, hypothyroidism, diabetes, presence of nodal blockers at admission, and increased PR interval (details of full propensity model available in eTable 2). Covariate balance was achieved in the inverse probability of treatment weighted sample (eTable 5, Supplemental Digital Content 1, http:// links.lww.com/CCM/C157).
Results of Secondary Analyses
The extent of bradycardia (normalized AUC of HR < 80 beats/ min) was also associated with significantly lower mortality, as depicted in Figure 2 (OR, 0.92 per beats/min; adjusted 
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Critical Care Medicine www.ccmjournal.org p < 0.001). Weighted mean HR was also significantly associated with mortality, where lower mean HRs were associated with lower mortality (OR, 1.03 per beats/min; p < 0.001) (Fig. 2) . In a sensitivity analysis excluding the last 6 hours of vasopressor data, the association between mortality and the extent of bradycardia was unchanged (OR, 0.92 per beats/min; adjusted p < 0.001). We found that the median change in HR from the hour before to the hour after initiation of vasopressors was small: median change was −1.0% (interquartile range, −5.1% to 3.3%). The change in HR for bradycardic patients was slightly, but significantly, lower than for never-bradycardic patients (median, − Elixhauser total, mean ± sd 5 ± 2 5 ± 2 5 ± 2 0.13
Congestive heart failure, n (%) 403 (26) 195 (28) 208 (24) 0.09 Diabetes, n (%) 538 (35) 238 (35) 300 (35) 0.99
Hypothyroidism, n (%) 304 (20) 170 (25) 134 (15) < 0.001
Cardiovascular function
Mean arterial pressure (weighted mean), mean ± sd 72 ± 6 73 ± 6 72 ± 7 0.52
Pacemaker (on admit), n (%) 112 (7) 69 (10) 43 (5) Our exploratory analysis of the association between APACHE II-adjusted mortality and various HR thresholds is displayed in Figure 3 . Visually, severity-adjusted mortality appeared to reach a nadir around 80 beats/min. Bradycardia (dichotomous) was associated with 2.1 more organ failure-free days to day 28, after controlling for covariates (p < 0.001). Organ failure-free days increased as extent of bradycardia increased (p < 0.001). Days free of specific (renal, cardiovascular, and respiratory) organ failures were also higher in bradycardic patients. Bradycardia (dichotomous) was also associated with a 0.55 (p = 0.03) increase in vasopressor-free days, after adjusting for covariates. Vasopressor-free days also increased (p = 0.001) as extent of bradycardia increased. Relative bradycardia was not a significant predictor of hospital or ICU LOS.
Although all patients received vasopressors, the distribution of individual vasopressors differed between bradycardic and never-bradycardic patients (eTable 4, Supplemental Digital Content 1, http://links.lww.com/CCM/C157). Bradycardic patients had lower mean vasopressor infusion rates (norepinephrine-equivalent doses, 0.10 vs 0.13 μg/kg/min; p = 0.004), but for longer duration (31 vs 20 hr; p < 0.001). The maximum dose of vasopressors did not differ between the groups (p = 0.31). Never-bradycardic patients more frequently received dobutamine infusions. The weighted mean of the MAP was the same for both groups (73 vs 72 mm Hg; p = 0.52).
Bradycardic patients were more likely to be taking a nodal blocking agent at admission (37% vs 26%; p < 0.001), but this was not a relevant predictor in the primary regression model of mortality. Of the bradycardic patients, 364 (52%) received medications that commonly induce bradycardia within three half-lives of the beginning of episodes of relative bradycardia. Relatively bradycardic patients who received bradycardia-inducing medications had a similar or lower mortality than never-bradycardic patients who received bradycardia-inducing medications (eTable 1, Supplemental Digital Content 1, http://links.lww.com/CCM/ C157).
Admission ECG data were available for 85% of patients. QRS duration and PR interval were both slightly longer in bradycardic patients; QTc did not differ. Presence of chronic atrial fibrillation was not significant in the primary regression model. An echocardiogram was available for review in 1,223 patients (79%). EF was similar among relatively bradycardic and neverbradycardic patients (mean, 57% vs 54%; p = 0.05). Among bradycardic patients, there was no significant difference in mortality between patients with and without a pacemaker present at admission (p = 0.16) (further results available in the online data supplement, Supplemental Digital Content 1, http://links.lww. com/CCM/C157).
DISCUSSION
In this large cohort of patients with septic shock, relative bradycardia was both common and associated with significantly higher survival, even after control for multiple covariates and the propensity to be relatively bradycardic. The association was robust with several definitions of relative bradycardia and multiple sensitivity analyses. Secondary outcomes, such as organ failure-free and vasopressor-free days, tracked the mortality outcomes.
Although earlier studies have suggested that sustained tachycardia is toxic in septic shock (16, 34) , our study improves upon prior observations in terms of its size, the use of propensity 
Predicted Probability of Mortality for Various Thresholds of Bradycardia
Heart Rate Threshold Predicted Probability of 28 Day Mortality (adjusted for APACHE II) Figure 3 . Predicted probability of 28-day mortality for various heart rate thresholds. APACHE = Acute Physiology and Chronic Health Evaluation.
adjustment to minimize the effect of confounding, and the exploration of lower HRs to include relative bradycardia.
Although it is plausible that bradycardia may simply be a surrogate for decreased disease severity and lower doses of vasopressors, our propensity adjustment suggests that such is not the case. Even after controlling for severity of illness, vasopressor infusions, comorbidities, and the probability of being bradycardic, relative bradycardia was strongly associated with higher survival.
The apparent association between relative bradycardia and mortality could be explained via multiple mechanisms. A promising possible mechanism appears to be the deleterious effect of adrenergic overstimulation, of which tachycardia persisting after volume expansion is an important marker. Additionally, bradycardia might improve outcomes by decreased cardiac work and increased coronary artery perfusion (35) . Although chronotropic incompetence has been associated with increased mortality in older patients (36), our results suggest that such a phenomenon is not relevant in septic shock.
Optimal thresholds for induced bradycardia are not well defined, and our results suggest the possibility that the survival effect appears to level off at HRs below 80. We selected a threshold of 80 a priori rather than a more extreme threshold, such as 50 or 60 beats/min, to decrease the possibility that bradycardia was the cause of shock rather than a marker of sympathovagal balance. Similar observations have motivated attempts to slow HR by administration of adrenergic antagonists ("β-blockers") during septic shock (37) (38) (39) (40) . Such efforts should be undertaken with caution; past studies with a goal of correcting physiologic variables, such as oxygen delivery, to "normal" levels have rarely improved mortality and may be toxic (41) (42) (43) .
Several factors were associated with bradycardia in our population, including advancing age, lower APACHE II score, hypothyroidism, diabetes, presence of a nodal blocker at admission, and mild conduction abnormalities. We could not formally distinguish well-treated hypothyroidism from myxedema coma, though the latter is rare. Hypothyroidism was a predictor of bradycardia, but it did not predict mortality. Although more patients who were on nodal blockers prior to admit were bradycardic during their admission, this also did not predict mortality. Partially controlled data from an Italian registry suggested that preadmission β blocker use may be associated with better outcomes (44) . Our study does not support this finding; larger (ultimately prospective) studies will be required to answer that question definitively.
Our study was limited by its retrospective, observational design. The most recent definition of septic shock includes the presence of an elevated lactate level as well as vasopressor administration after adequate fluid resuscitation (2) . The retrospective design of this study did not allow for collection of data on these additional variables that may have influenced outcomes, such as details regarding fluid resuscitation, time to antibiotic administration, and lactate clearance. Although IPTW for propensity adjustment limits the influence of confounding, residual confounding may still have affected our findings. And, as always, our nonrandomized data may identify correlation rather than causation.
CONCLUSIONS
We studied more than 1,500 patients with septic shock on vasopressors and compared outcomes between patients with or without at least one episode of relative bradycardia (HR < 80 beats/min). Such relative bradycardia was associated with improved 28-day mortality. Our results provide further support for clinical equipoise in investigations of induced relative bradycardia for patients with septic shock.
